AZNCF News and Press, Astrazeneca plc

Klaviyo Inc. Series A (KVYO) is expected to report $0.04 for Q4 2025 Diodes Incorporated (DIOD) is expected to report $0.26 for Q4 2025 CRISPR Therapeutics AG (CRSP) is expected to report $-1.15 for Q4 2025 Brighthouse Financial Inc. (BHF) is expected to report $5.19 for Q4 2025 B...

Astrazeneca plc (AZNCF) is expected to report $2.18 for Q4 2025

2026-01-15 12:28:48 ET Introduction The iShares MSCI United Kingdom ETF ( EWU ) has delivered a stellar ~39% gain over the past year, roughly double the ~19% return of the Vanguard S&P 500 ETF ( VOO ): EWU vs VOO over the past year (Seeking Alpha) ...

2026-01-13 16:15:59 ET AstraZeneca PLC (AZN) 44th Annual J.P. Morgan Healthcare Conference January 11, 2026 7:00 PM EST... Read the full article on Seeking Alpha For further details see: AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-10 10:00:00 ET Since my last article, "AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors," AstraZeneca shares (NASDAQ: AZN ) (OTCPK: AZNCF ) have risen 26.9%.... Read the full article on Seeking Alpha For further details see: Astr...

2026-01-08 07:20:06 ET More on Gilead Sciences, CVS , etc. Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript Roche Holding AG (RHHBY) Shareholder/Analyst Call - Slideshow CVS Health Corporation (CVS) Analyst/Investor Day Prepared Remarks Transcript ...

2025-12-29 09:20:00 ET I am expecting 2026 to be a big year for the S&P 500 Index ( SPY , SPX , SP500 ), and it is quite simply because the pharmaceutical sector is going to lead the way. Thus, I'm incorporating a Strong Buy rating. One big reason would be because of...

2025-12-18 16:25:34 ET It has been a very good year for the British pharmaceutical stock GSK plc ( GSK ), which is up by ~46% YTD. This far exceeds the performance of the healthcare sector, as evident from the 13.5% returns on the State Street Health Care Select Sector SPDR ETF ( ...

2025-12-10 10:26:49 ET Introduction AstraZeneca ( AZN ) is looking to be the first biopharma to throw off the cloak of cyclicality due to their work in optimizing the commercial and pipeline asset base. Despite being able to leverage experience and economies of scale, big pharma...

2025-11-27 07:20:44 ET Introduction As the year comes to an end, we must be thankful for the therapies that are in late clinical stages. Most importantly, patients are set to benefit immensely. But nearly every trial candidate has implications beyond just patients. The approval of a...